A global survey of pathologists conducted by the International Association for the Study of Lung Cancer pathology committee highlighted marked heterogeneity in PD-L1 testing across regions and laboratories with regard to antibody clones, IHC assays, samples, turnaround times, and quality assurance measures (86). The gene discussed is CD274; the disease is lung carcinoma.